Literature DB >> 28263886

Gene editing in mouse zygotes using the CRISPR/Cas9 system.

Benedikt Wefers1, Sanum Bashir2, Jana Rossius3, Wolfgang Wurst4, Ralf Kühn5.   

Abstract

The generation of targeted mouse mutants is a key technology for biomedical research. Using the CRISPR/Cas9 system for induction of targeted double-strand breaks, gene editing can be performed in a single step directly in mouse zygotes. This article covers the design of knockout and knockin alleles, preparation of reagents, microinjection or electroporation of zygotes and the genotyping of pups derived from gene editing projects. In addition we include a section for the control of experimental settings by targeting the Rosa26 locus and PCR based genotyping of blastocysts.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CRISPR; Cas9; Gene editing; Mouse; Zygotes

Mesh:

Substances:

Year:  2017        PMID: 28263886     DOI: 10.1016/j.ymeth.2017.02.008

Source DB:  PubMed          Journal:  Methods        ISSN: 1046-2023            Impact factor:   3.608


  14 in total

Review 1.  Gene-edited CRISPy Critters for alcohol research.

Authors:  Gregg E Homanics
Journal:  Alcohol       Date:  2018-03-07       Impact factor: 2.405

2.  Efficient gene editing in a medaka (Oryzias latipes) cell line and embryos by SpCas9/tRNA-gRNA.

Authors:  Qihua Pan; Junzhi Luo; Yuewen Jiang; Zhi Wang; Ke Lu; Tiansheng Chen
Journal:  J Zhejiang Univ Sci B       Date:  2022-01-15       Impact factor: 3.066

3.  Regulation of the Natriuretic Peptide Receptor 2 (Npr2) by Phosphorylation of Juxtamembrane Serine and Threonine Residues Is Essential for Bifurcation of Sensory Axons.

Authors:  Hannes Schmidt; Deborah M Dickey; Alexandre Dumoulin; Marie Octave; Jerid W Robinson; Ralf Kühn; Robert Feil; Lincoln R Potter; Fritz G Rathjen
Journal:  J Neurosci       Date:  2018-09-24       Impact factor: 6.167

4.  Simple and reliable detection of CRISPR-induced on-target effects by qgPCR and SNP genotyping.

Authors:  Isabel Weisheit; Joseph A Kroeger; Rainer Malik; Benedikt Wefers; Peter Lichtner; Wolfgang Wurst; Martin Dichgans; Dominik Paquet
Journal:  Nat Protoc       Date:  2021-02-17       Impact factor: 13.491

5.  A bispecific antibody targeting GPC3 and CD47 induced enhanced antitumor efficacy against dual antigen-expressing HCC.

Authors:  Kaixin Du; Yulu Li; Juan Liu; Wei Chen; Zhizhong Wei; Yong Luo; Huisi Liu; Yonghe Qi; Fengchao Wang; Jianhua Sui
Journal:  Mol Ther       Date:  2021-01-09       Impact factor: 11.454

Review 6.  New approaches to moderate CRISPR-Cas9 activity: Addressing issues of cellular uptake and endosomal escape.

Authors:  Maja van Hees; Sofie Slott; Anders Højgaard Hansen; Heon Seok Kim; Hanlee P Ji; Kira Astakhova
Journal:  Mol Ther       Date:  2021-06-04       Impact factor: 11.454

Review 7.  Orthotopic T-Cell Receptor Replacement-An "Enabler" for TCR-Based Therapies.

Authors:  Kilian Schober; Thomas R Müller; Dirk H Busch
Journal:  Cells       Date:  2020-06-01       Impact factor: 6.600

8.  Novelty-induced hyperactivity and suppressed cocaine induced locomotor activation in mice lacking threonine 53 phosphorylation of dopamine transporter.

Authors:  Durairaj Ragu Varman; Mark A Subler; Jolene J Windle; Lankupalle D Jayanthi; Sammanda Ramamoorthy
Journal:  Behav Brain Res       Date:  2021-03-29       Impact factor: 3.352

9.  An optimized electroporation approach for efficient CRISPR/Cas9 genome editing in murine zygotes.

Authors:  Simon E Tröder; Lena K Ebert; Linus Butt; Sonja Assenmacher; Bernhard Schermer; Branko Zevnik
Journal:  PLoS One       Date:  2018-05-03       Impact factor: 3.240

10.  The Trem2 R47H Alzheimer's risk variant impairs splicing and reduces Trem2 mRNA and protein in mice but not in humans.

Authors:  Xianyuan Xiang; Thomas M Piers; Benedikt Wefers; Kaichuan Zhu; Anna Mallach; Bettina Brunner; Gernot Kleinberger; Wilbur Song; Marco Colonna; Jochen Herms; Wolfgang Wurst; Jennifer M Pocock; Christian Haass
Journal:  Mol Neurodegener       Date:  2018-09-06       Impact factor: 14.195

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.